Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Medical Genetics

The PNPLA6 Family: Understanding the Spectrum

At a Glance

Laurence-Moon syndrome belongs to a broader PNPLA6-related disorder spectrum. Historical labels such as Boucher-Neuhäuser, Gordon-Holmes, Oliver-McFarlane, and SPG39 describe overlapping patterns, so care should be guided by each person’s symptoms and screening needs.

When you receive a diagnosis of Laurence-Moon syndrome, it is natural to focus heavily on that specific name. However, modern genetics has revealed that your condition is part of a larger “family” of overlapping conditions known as PNPLA6-associated disorders [1][2].

Think of the PNPLA6 gene as creating a continuous spectrum of symptoms. Because these conditions overlap so much, the boundaries between them are not strict, and many people have “hybrid” or atypical features that don’t perfectly fit into one historical box [3].

The PNPLA6 “Family” of Syndromes

There are five main historical labels that doctors used to think were separate diseases but are now known to be different presentations of the same genetic spectrum [1][4].

1. Boucher-Neuhäuser Syndrome (BNS)

This presentation classically involves a “triad” of symptoms: ataxia (balance issues), chorioretinal dystrophy (vision loss), and hypogonadotropic hypogonadism (hormonal/puberty issues) [5][6].

2. Gordon-Holmes Syndrome (GHS)

In this version of the spectrum, balance issues (ataxia) and hormonal issues are prominent [7]. Some people with GHS may have mild or highly variable vision loss [8].

3. Oliver-McFarlane Syndrome (OMS)

OMS often appears very early in life. It is frequently distinguished by unique physical features like trichomegaly (unusually long, thick eyelashes and eyebrows) and sparse hair on the head [9][10]. It also commonly involves short stature and multiple deficiencies in pituitary hormones [11].

4. Spastic Paraplegia Type 39 (SPG39)

This label focuses primarily on nerve symptoms in the legs, causing spasticity (stiffness) and weakness that can make walking difficult [1][12]. Some patients may only have leg issues, while others eventually develop vision or hormonal symptoms [12].

5. Laurence-Moon Syndrome (LMS)

This label typically describes a combination of vision loss, ataxia, spasticity, and hormonal changes, though the exact mix and severity of these features vary from person to person [1][4].

Comparing the Typical Features

Feature Laurence-Moon Boucher-Neuhäuser Gordon-Holmes Oliver-McFarlane SPG39
Vision Loss Common Common Variable Common Variable
Balance (Ataxia) Common Common Common Variable Variable
Leg Stiffness Common Variable Variable Not typical Common
Hormone Issues Common Common Common Common Variable
Long Lashes Not typical Not typical Not typical Common Not typical

Note: This table reflects typical historical descriptions. Because this is a continuous spectrum, an individual may experience symptoms outside these historical boundaries.

Why the Spectrum Concept Matters to You

It can be frustrating when different doctors use different names or simply write “PNPLA6-related disorder” in your chart. However, understanding that you are on a spectrum is important for your care:

  • Symptoms Guide Management: While your specific genetic diagnosis is crucial for counseling and screening, day-to-day management follows your actual symptoms [2]. If you have balance issues, your care team will focus on physical therapy regardless of whether the historical label is GHS or LMS.
  • Predictive Screening: Knowing the other syndromes in the family helps your doctor know what to look for. For example, since Oliver-McFarlane involves growth hormone and adrenal issues, your endocrinologist will know to periodically evaluate you for broader pituitary deficiencies [11][13].
  • A Shared Community: You are not just a “Laurence-Moon patient”; you are part of a larger community of people with PNPLA6-related disorders. This opens up more opportunities for support groups, registries, and research that cover the entire spectrum [1].

Common questions in this guide

What is the PNPLA6-related disorder spectrum?
The PNPLA6-related disorder spectrum is a group of overlapping conditions associated with the PNPLA6 gene. Laurence-Moon syndrome, Boucher-Neuhäuser syndrome, Gordon-Holmes syndrome, Oliver-McFarlane syndrome, and SPG39 are historical labels for patterns within this spectrum, and some people have features of more than one.
How is Laurence-Moon syndrome related to the other PNPLA6 syndromes?
These names are not always completely separate diseases in modern genetics. They describe different combinations of vision, balance, leg stiffness, hair, growth, and hormone features within one overlapping PNPLA6-related spectrum.
What symptoms can occur with Laurence-Moon syndrome?
Symptoms can include vision loss, balance or coordination problems, leg stiffness, weakness, difficulty walking, and hormonal or puberty changes. The combination and severity vary, and a person may have features associated with more than one historical pattern.
Why might someone with a PNPLA6 diagnosis need hormone screening?
Some PNPLA6-related presentations can involve growth hormone, other pituitary hormones, or adrenal problems. Periodic evaluation can help a clinician decide whether broader hormone monitoring is needed based on the person's symptoms and history.
Does the historical label determine treatment for Laurence-Moon syndrome?
Usually, day-to-day management is guided by the symptoms a person actually has rather than by the historical label alone. For example, balance or walking problems may lead to physical therapy, while vision and hormone concerns may require monitoring by appropriate specialists.

Get notified when new evidence is published on Laurence-Moon syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    PNPLA6 disorders: what's in a name?

    Liu J, Hufnagel RB

    Ophthalmic genetics 2023; (44(6)):530-538 doi:10.1080/13816810.2023.2254830.

    PMID: 37732399
  2. 2

    Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders.

    Liu J, He Y, Lwin C, et al.

    Brain : a journal of neurology 2024; (147(6)):2085-2097 doi:10.1093/brain/awae055.

    PMID: 38735647
  3. 3

    Neuropathy target esterase activity predicts retinopathy among PNPLA6 disorders.

    Liu J, He Y, Lwin C, et al.

    bioRxiv : the preprint server for biology 2023; doi:10.1101/2023.06.09.544373.

    PMID: 37333224
  4. 4

    Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature.

    Nanetti L, Di Bella D, Magri S, et al.

    Frontiers in neurology 2021; (12()):793547 doi:10.3389/fneur.2021.793547.

    PMID: 35069422
  5. 5

    A novel PNPLA6 compound heterozygous mutation identified in a Chinese patient with Boucher‑Neuhäuser syndrome.

    Zheng R, Zhao Y, Wu J, et al.

    Molecular medicine reports 2018; (18(1)):261-267 doi:10.3892/mmr.2018.8955.

    PMID: 29749493
  6. 6

    Novel variants in PNPLA6 causing syndromic retinal dystrophy.

    Wu S, Sun Z, Zhu T, et al.

    Experimental eye research 2021; (202()):108327 doi:10.1016/j.exer.2020.108327.

    PMID: 33141049
  7. 7

    Different Cerebellar Ataxia Phenotypes Associated with Mutations of the PNPLA6 Gene in Brazilian Patients with Recessive Ataxias.

    Teive HAG, Camargo CHF, Sato MT, et al.

    Cerebellum (London, England) 2018; (17(3)):380-385 doi:10.1007/s12311-017-0909-y.

    PMID: 29248984
  8. 8

    Retinal Pigment Epithelial Changes in Gordon Holmes Syndrome.

    Lu ES, Kozek LK, Martinez-Velazquez L, et al.

    Journal of vitreoretinal diseases 2026; 24741264261442895 doi:10.1177/24741264261442895.

    PMID: 42137175
  9. 9

    Oliver McFarlane syndrome: two new cases and a review of the literature.

    Lisbjerg K, Andersen MKG, Bertelsen M, et al.

    Ophthalmic genetics 2021; (42(4)):464-473 doi:10.1080/13816810.2021.1904419.

    PMID: 33818269
  10. 10

    Case Report: Novel compound heterozygous mutations in PNPLA6 gene associated with Oliver-McFarlane syndrome.

    Zheng J, Wang Z, Li K, et al.

    Frontiers in genetics 2025; (16()):1660243 doi:10.3389/fgene.2025.1660243.

    PMID: 41282473
  11. 11

    New insights into Oliver-McFarlane syndrome: adrenocortical hypofunction and variable expressivity in a Chinese sibling pair.

    Du C, Yu T, Liu S, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2026; (39(6)):622-627 doi:10.1515/jpem-2025-0731.

    PMID: 41846525
  12. 12

    A novel PNPLA6 mutation in a Turkish family with intractable Holmes tremor and spastic ataxia.

    Emekli AS, Samanci B, Şimşir G, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(4)):1535-1539 doi:10.1007/s10072-020-04869-6.

    PMID: 33210227
  13. 13

    Novel PNPLA6 Variants: Hypogonadotropic Hypogonadism, Pituitary Hypoplasia, Anosmia, and Cerebellar Atrophy in Siblings.

    Hussain MA, Kumar V, Chapla A, et al.

    JCEM case reports 2026; (4(1)):luaf286 doi:10.1210/jcemcr/luaf286.

    PMID: 41356532

This page is for informational purposes only and does not constitute medical advice about Laurence-Moon syndrome or PNPLA6-related disorders. Your genetics, neurology, eye-care, and endocrine specialists should interpret your symptoms and decide what screening or treatment you need.